Revvity Targets 6% to 8% Organic Growth and Double-Digit EPS Growth at Investor Day
Revvity laid out a long-range plan on Friday that calls for 6% to 8% organic revenue growth, steady margin gains and double-digit growth in adjusted earnings per share, according to the presentation for its 2026 Investor Day filed with an 8-K.
Chief Executive Prahlad Singh and other senior managers were set to present the plan at the event, which was scheduled to begin at 9:00 a.m. Eastern time, the company said. Singh said in the accompanying press release that Revvity is "confident in our ability to deliver sustained, above-market growth and long-term shareholder value."
The long-term targets
The presentation's long-term financial outlook lists:
- Organic revenue growth of 6% to 8%, which Revvity says is 200 basis points above its underlying markets
- 75 basis points of operating margin expansion, which another slide breaks into 25 basis points a year from gross margin and 50 basis points a year from operating leverage and cost efficiencies in selling, general and administrative costs
- Double-digit adjusted EPS growth
Targets by business
Revvity set a long-range organic growth target of 7% to 9% for its Life Sciences segment, made up of 6% to 8% for Life Sciences Solutions and 10% to 12% for its Signals software business, which is measured on annualized portfolio value. For Diagnostics, the target is 5% to 7%, with 7% to 9% for immunodiagnostics and 3% to 5% for reproductive health.
2026 baseline and 2027
The presentation puts 2026 revenue at an estimated $2.9 billion and 2026 adjusted operating margin at an estimated 28.8%, the company's own projections. Its slide on 2027 considerations points to an estimated 6% organic growth, net interest the company estimated at $85 million, a tax rate it estimated at 19% and a flat share count. Revvity said formal 2027 guidance will come on its fourth-quarter earnings call.
Capital plans
For 2027 through 2031, Revvity said it intends to pursue targeted acquisitions in Life Sciences, make consistent share repurchases and maintain its existing dividend. It cited an estimated $5 billion of capital capacity through 2031, the company said, along with a commitment to an investment-grade credit rating.
Sources
- Form 8-K, Exhibit 99.1 press release and Exhibit 99.2 Investor Day 2026 presentation, Revvity, Inc., filed Nov. 13, 2026, accession 0001628280-26-073578
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.